Probi probiotics reduce gut problems in connection with cancer radiotherapy

PRESS RELEASE

A randomized, double-blind, placebo-controlled trial with Probi’s two probiotic strains, HEAL9TM and LP6595, was shown to reduce gastrointestinal problems for women receiving pelvic radiotherapy.

The 3-armed study included 75 women with gynecological cancer receiving pelvic radiotherapy. The patients were either given a high or a low dose of the combined probiotic strains HEAL9TM and LP6595 or placebo and was conducted on two sites in Sweden.

“When receiving radiotherapy in connection with gynecological cancer, women often experience gastrointestinal problems during and after the therapy. This study showed significantly reduced severity and frequency of both abdominal pain and defecation urgency,” explains Niklas Larsson, Senior Director Scientific Affairs & IP at Probi.

“It is extremely rewarding to see that such a vulnerable group may be helped in a very exposed situation by consuming our probiotic strains. This is completely in line with our vision to provide probiotics for healthier lives by being an innovative frontrunner,” says Tom Rönnlund, CEO at Probi.

The study “Decreasing the Adverse Effects in Pelvic Radiation Therapy: A Randomized Controlled Trial Evaluating the Use of Probiotics” was recently published in Advances in Radiation Oncology (2022) 8, 101089 and can be found here: https://doi.org/10.1016/j.adro.2022.101089

For further information, please contact:

Tom Rönnlund, CEO, Probi®

Phone: +46 46 286 89 40, E-mail: trd@probi.com

Niklas Larsson, Senior Director Scientific Affairs & IP, Probi®

Phone: +46 76 118 26 99, E-mail: niklas.larsson@probi.com

Charlotte Beyerholm, Director Marketing & Global Communication, Probi®

Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com

ABOUT PROBI

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.

Probi® is a registered trademark and HEAL9TM is a trademark of Probi AB.